In 2025, the net profit attributable to shareholders of Beijing Chunlizhengda Medical Instruments (01858) was approximately 272 million yuan, a year-on-year increase of 117.72%.

Beijing Chunlizhengda Medical Instruments (01858) announced its performance report for the year 2025, with total operating revenue of approximately 1.044 billion yuan, a year-on-year growth of 29.52%; net profit attributable to owners of the parent company is approximately 272 million yuan, a year-on-year growth of 117.72%; basic earnings per share is 0.71 yuan. During the reporting period, the company's growth potential continued to be released after the landing of product centralized procurement, international business steadily progressed, and internal and external synergy drove steady revenue growth; at the same time, the company continued to optimize operational management and resource allocation, further improving operational efficiency and profitability, jointly promoting good growth in performance. The announcement stated that the main reasons for the performance growth are: as the normalization of national centralized procurement of orthopedic consumables advances, the company relies on a perfect channel coverage network and a rich product system, steadily increasing product sales volume, continuously expanding domestic business scale and market share, driving profit levels steadily. The company continues to promote its internationalization strategy, relying on product technology and quality standards that have reached international advanced levels, achieving continuous expansion and breakthroughs in business in the international market, with overseas revenue steadily increasing, providing important support for the overall performance growth of the company. At the same time, the company focuses on refined operational management, optimizing operational efficiency; through scale production, further strengthening economies of scale, overall operational efficiency and profitability have been significantly improved.